SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM).

被引：0
|
作者：
Garland, Linda L.
Ou, Sai-Hong
Moon, James
Mack, Philip C.
Testa, Joseph
Tsao, Anne S.
Wozniak, Antoinette J.
Gandara, David R.
机构：
[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA
[2] UC Irvine Med Ctr, Chao Family Comprehens Canc Ctr, Orange, CA USA
[3] Southwest Oncol Grp Stat Ctr, Seattle, WA USA
[4] Univ Calif Davis, Sacramento, CA 95817 USA
[5] Fox Chase Canc Ctr, Buckingham, PA USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[8] UC Davis Canc Ctr, Div Hematol & Oncol, Sacramento, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7083
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium
    Milowsky, M. I.
    Trout, A.
    Regazzi, A. M.
    Garcia-Grossman, I.
    Flaherty, A.
    Tickoo, S.
    Al-Ahmadie, H.
    Bajorin, D. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] A phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM).
    Wozniak, Antoinette J.
    Schneider, Bryan J.
    Kalemkerian, Gregory Peter
    Daly, Robert Michael
    Chen, Wei
    Ventimiglia, Jaclyn
    Nagasaka, Misako
    Zauderer, Marjorie Glass
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] A phase II trial of gefitinib in patients with malignant pleural mesothelioma (MPM)
    Lee, C. W.
    Anderson, H.
    Martins, H.
    Rao, S. C.
    Sauciuc, D.
    Laurie, S. A.
    Morzycki, W.
    MacNeil, M. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results
    Vannucchi, Alessandro M.
    Guglielmelli, Paola
    Lupo, Letizia
    Finazzi, Maria Chiara
    Tozzi, Lorenzo
    Biamonte, Flavia
    Masciulli, Arianna
    Susini, Maria Chiara
    Pancrazzi, Alessandro
    Finazzi, Guido
    Paratore, Simona
    Marchioli, Roberto
    Bosi, Alberto
    Barbui, Tiziano
    Rambaldi, Alessandro
    Barosi, Giovanni
    BLOOD, 2010, 116 (21) : 143 - 143
  • [35] A Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM)
    Wozniak, A.
    Schneider, B.
    Kalemkerian, G.
    Daly, R.
    Chen, W.
    Ventimiglia, J.
    Nagasaka, M.
    Zauderer, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S343 - S343
  • [36] Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)
    Castagneto, B.
    Botta, M.
    Aitini, E.
    Spigno, F.
    Degiovanni, D.
    Alabiso, O.
    Serra, M.
    Muzio, A.
    Carbone, R.
    Buosi, R.
    Galbusera, V.
    Piccolini, E.
    Giaretto, L.
    Rebella, L.
    Mencoboni, M.
    ANNALS OF ONCOLOGY, 2008, 19 (02) : 370 - 373
  • [37] PHASE II STUDY OF MTOR-INHIBITOR RAD001 AND ERLOTINIB FOR ADVANCED, GEMCITABINE-REFRACTORY PANCREATIC CANCER
    Javle, M.
    Reddy, S.
    Varadhachary, G.
    Kaseb, A.
    Fogelman, D.
    Wolff, R.
    Abbruzzese, J.
    PANCREAS, 2008, 37 (04) : 476 - 476
  • [38] Carboplatin and Gemcitabine chemotherapy for malignant pleural mesothelioma (MPM): A phase II study of the GSTPV
    Aversa, SML
    Arcuri, C
    De Pangher, V
    Favaretto, A
    Endrizzi, L
    Sartore, F
    Giunta, G
    Toso, S
    Biasion, R
    Paccagnella, A
    ANNALS OF ONCOLOGY, 1998, 9 : 117 - 117
  • [39] Phase II study of MTOR-inhibitor RAD001 and erlotinib for advanced, gemcitabine-refractory pancreatic cancer
    Javle, M.
    Fogelman, D.
    Kaseb, A.
    Varadhachary, G.
    Wolff, R.
    Abbruzzese, J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 104 - 104
  • [40] The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines
    Brigette B. Y. Ma
    Vivian W. Y. Lui
    Edwin P. Hui
    Cecilia P. Y. Lau
    Kakiu Ho
    Margaret H. L. Ng
    S. H. Cheng
    Sai-Wah Tsao
    Anthony T. C. Chan
    Investigational New Drugs, 2010, 28 : 413 - 420
12345